BCAL Diagnostics Ltd

Healthcare AU BDX

0.078AUD
-0.002(2.50%)

Last update at 2025-05-02T04:42:00Z

Day Range

0.080.08
LowHigh

52 Week Range

0.080.18
LowHigh

Fundamentals

  • Previous Close 0.08
  • Market Cap31.47M
  • Volume41625
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-6.90861M
  • Revenue TTM2.62M
  • Revenue Per Share TTM0.008
  • Gross Profit TTM 2.62M
  • Diluted EPS TTM-0.03

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -5.06176M -3.38549M -1.52497M -0.69636M -0.42996M
Minority interest - - - - -
Net income -5.06176M -3.38549M -1.52497M -0.69636M -0.42996M
Selling general administrative 3.27M 1.87M 0.55M 0.66M 0.47M
Selling and marketing expenses - 0.13M - - -
Gross profit - - - - -
Reconciled depreciation 0.11M 0.02M - - -
Ebit -4.72515M -3.91451M -0.93392M -0.69636M -0.42486M
Ebitda -7.78479M -3.89390M - - -
Depreciation and amortization - 0.02M - - -
Non operating income net other - - - - -
Operating income -5.10787M -3.91451M -1.52522M -0.69687M -0.42658M
Other operating expenses - 3.91M - - -
Interest expense - 0.00000M 0.00000M 0.00000M 0.00000M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.05M 0.02M 0.00025M 0.00050M 0.00339M
Net interest income 0.05M 0.02M - - -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - -0.01864M - - -
Total revenue 2.79M 0.72M 0.28M 0.44M 0.26M
Total operating expenses - 3.91M - - -
Cost of revenue - - - - -
Total other income expense net 2.79M 0.51M - - -
Discontinued operations - - - - -
Net income from continuing ops -5.06175M -3.38549M - - -
Net income applicable to common shares -5.06175M -3.38549M -1.52497M -0.69636M -0.42996M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 12.27M 8.37M 10.59M 4.13M 0.82M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.08M -0.00000M 4.00M 0.13M -
Total liab 3.68M 3.16M 0.95M 0.53M 0.38M
Total stockholder equity 8.59M 5.21M 9.64M 3.61M 0.44M
Deferred long term liab - - - - -
Other current liab 1.13M 0.04M 0.67M 0.01M 0.00814M
Common stock 28.90M 19.28M 18.87M 9.46M 4.94M
Capital stock - 19.28M 18.87M - -
Retained earnings -20.97596M -14.61492M -9.55317M -6.16768M -4.64271M
Other liab - 0.00000M - - -
Good will - - - - -
Other assets 0.00000M - - - -
Cash 6.47M 3.17M 5.57M 3.41M 0.42M
Cash and equivalents - - - - -
Total current liabilities 2.60M 2.26M 0.95M 0.53M 0.08M
Current deferred revenue 0.28M - - - -
Net debt -4.94914M - -5.57142M - -
Short term debt 0.44M 0.00000M 0.00000M 0.00000M 0.00000M
Short long term debt - - - - -
Short long term debt total 1.52M - - - 0.30M
Other stockholder equity - 0.55M 0.32M 0.32M 0.14M
Property plant equipment - 2.17M 0.14M 0.00385M 0.00000M
Total current assets 9.34M 6.20M 10.46M 4.13M 0.82M
Long term investments - - - - -
Net tangible assets - 5.21M 9.64M 3.61M 0.44M
Short term investments - 0.00000M 4.00M - -
Net receivables 2.78M 2.69M 0.01M 0.35M 0.40M
Long term debt - - 0.00000M 0.00000M 0.30M
Inventory - - - - -
Accounts payable 0.74M 1.58M 0.28M 0.25M 0.06M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.67M - 0.32M - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other -0.00000M - - - -
Deferred long term asset charges - - - - -
Non current assets total 2.93M 2.17M 0.14M - -
Capital lease obligations - 1.06M - - -
Long term debt total - 0.90M 0.00000M 0.00000M 0.30M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 4.00M -4.00000M -4.00000M -4.00000M -4.00000M
Change to liabilities 0.78M 0.05M 0.44M 0.03M -0.08972M
Total cashflows from investing activities 3.64M -4.02576M -0.00385M -0.00381M -0.00747M
Net borrowings -0.03676M -0.03676M -0.03676M 0.30M 0.30M
Total cash from financing activities 0.01M 9.41M 4.20M 0.81M 0.50M
Change to operating activities - - - - -
Net income -5.06175M -3.38549M -1.52497M -0.69636M -0.42996M
Change in cash -2.39732M 2.16M 2.99M 0.14M -0.03248M
Begin period cash flow 5.57M 3.41M - - -
End period cash flow 3.17M 5.57M 3.41M - -
Total cash from operating activities -6.04809M -3.21932M -1.20642M -0.66165M -0.52501M
Issuance of capital stock 0.05M 10.03M - - -
Depreciation 0.11M 0.02M 0.02M 0.00773M 0.00355M
Other cashflows from investing activities 4.00M -4.00000M - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables -2.14255M -0.28884M -0.31767M -0.14402M -0.00895M
Sale purchase of stock 0.05M -0.62179M 4.41M 0.51M 0.50M
Other cashflows from financing activities 0.00000M -4.02576M -0.20835M -0.20835M -0.20835M
Change to netincome 0.27M 0.38M 0.19M 0.14M 0.00007M
Capital expenditures 0.36M 4.03M 0.00385M 0.00381M 0.00747M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 1.04M 0.29M 0.40M 0.28M 0.24M
Stock based compensation - - - - -
Other non cash items - - - - -
Free cash flow -6.04809M -4.02576M - - -

Peer Comparison

Sector: Healthcare Industry: Diagnostics & Research

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BDX
BCAL Diagnostics Ltd
-0.002 2.50% 0.08 - - 11.31 3.16 - -1.8009
SHL
Sonic Healthcare Ltd
0.32 1.24% 26.06 22.90 20.75 1.35 1.52 1.80 9.58
HLS
Healius Ltd
-0.01 0.66% 1.50 - 131.58 0.61 1.03 1.34 10.14
IDX
Integral Diagnostics Ltd
-0.01 0.42% 2.39 117.25 17.09 1.78 1.29 2.84 18.89
ACL
Australian Clinical Labs Ltd
0.01 0.32% 3.14 21.00 15.06 0.85 3.67 1.27 4.98

Reports Covered

Stock Research & News

Profile

BCAL Diagnostics Limited, a screening and diagnostic company, engages in developing a novel blood screening test to improve the diagnosis and monitoring of breast cancer. It develops BREASTEST, a laboratory developed test or in-house in vitro diagnostic blood test. The company was incorporated in 2010 and is headquartered in Sydney, Australia.

BCAL Diagnostics Ltd

50 Clarence Street, Sydney, NSW, Australia, 2000

  • 61 2 9078 7671

Key Executives

Name Title Year Born
Ms. Jayne Andrea Shaw Co-Founder & Exec. Chairman NA
Dr. John G. Hurrell B.Sc, Fulbright Fel, M.Sc(Qual), Ph.D. Chief Exec. Officer NA
Hon. Ronald Anthony Phillips A.O. Co-Founder & Non-Exec. Director NA
Dr. Amani Batarseh Ph.D. Chief Scientist Officer NA
Mr. Guy Adrian Robertson B.Com., B.Comm(Hons.), C.A., CA, MAICD CFO & Company Sec. 1954
Dr. Jane Ryan Bsc (Hons), M.A.I.C.D., Ph.D. Chief Operating Officer 1959
Sean Kennedy Director of Corp. Fin. NA
Ms. Rebecca Shaw Marketing Mang. NA
Ms. Jayne Andrea Shaw Co-Founder & Executive Chairman NA
Ms. Jayne Andrea Shaw Co-Founder & Executive Chairman NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.